WO2013086506A1 - Idh1-mutated human glioblastoma cell lines and xenografts - Google Patents

Idh1-mutated human glioblastoma cell lines and xenografts Download PDF

Info

Publication number
WO2013086506A1
WO2013086506A1 PCT/US2012/068774 US2012068774W WO2013086506A1 WO 2013086506 A1 WO2013086506 A1 WO 2013086506A1 US 2012068774 W US2012068774 W US 2012068774W WO 2013086506 A1 WO2013086506 A1 WO 2013086506A1
Authority
WO
WIPO (PCT)
Prior art keywords
xenograft
gene
cell
defective
test compound
Prior art date
Application number
PCT/US2012/068774
Other languages
French (fr)
Inventor
Hai Yan
Darrell D. BIGNER
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Priority to US14/364,029 priority Critical patent/US20140356291A1/en
Publication of WO2013086506A1 publication Critical patent/WO2013086506A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Definitions

  • One aspect of the invention is an isolated human GBM xenograft identified as TB08-0714 (7DH7R132H homozygous) or as TB08-0537 (7DH7R132H heterozygous).
  • Another aspect of the invention is an isolated human GBM cell line identified as TB08-0714 (7DH7R132H homozygous) or as TB08-0537 (7DH7R132H heterozygous).
  • a method determines the effect of a test compound on DNA accumulation in an IDHl gene-defective cell line or xenograft of TB08-0714 (7DH7R132H homozygous) or TB08-0537 ( DH7R132H heterozygous).
  • the IDHl gene-defective cell line or xenograft is incubated in the presence and absence of the test compound.
  • the DNA content in the IDHl gene-defective cell or xenograft is determined.
  • the test compound is selected if it causes DNA accumulation in the IDHl gene- defective cell or xenograft.
  • a method screens for potential anti-tumor agents using an IDHl gene-defective cell line or xenograft.
  • An IDHl gene-defective cell or xenograft (TB08-0714 (7DH7R132H homozygous) or TB08-0537 ( DH7R132H heterozygous)) is incubated in the presence and absence of the anti-tumor agents.
  • Cell viability or apoptosis of the IDHl gene-defective cell or xenograft is determined.
  • Anti-tumor agents which reduce cell viability or induce apoptosis in the IDHl gene-defective cell or xenograft are selected.
  • a method screens for the effect of a test compound.
  • a xenograft derived from IDHl gene-defective cells (TB08- 0714 (7DH7R132H homozygous) or TB08-0537 (7DH7R132H heterozygous) is incubated in the presence and absence of the test compound. Tumor morphology of the cells or xenograft is determined. A test compound that reduces the cancerous morphology or increases the normal morphology is selected.
  • FIG. 1 provides a Kaplan-Meir curve for IDH1 mutant xenoline NOD SCID IC.
  • the 08-0537 or 08-0714 cells were injected intracranially for this survival study.
  • the 50% survival time is 52 days and 58 days for 08-0537 and 08-0714 respectively.
  • FIG. 2 shows IDH1 mutant tumor in NOD SCID mice (Xeno 08-0537, prefrontal injection)
  • the xenograft images were taken from NOD SCID mice that have been intracranially injected with either 08-0537 cells. The mice were sacrificed and the brains were fixed for sections and pathological assessment when the mice showed symptoms.
  • FIG. 3 shows IDH1 mutant tumor in NOD SCID mice ( Xeno 08-0714, prefrontal injection)
  • NOD SCID mice Xeno 08-0714, prefrontal injection
  • the xenograft images were taken from NOD SCID mice that have been intracranially injected with either 08-0714 cells. The mice were sacrificed and the brains were fixed for sections and pathological assessment when the mice showed symptoms
  • IDH1 gene mutations that affect amino acid 132 of IDH1 occur in an exceptionally high frequency (more than 70%) in gliomas. IDH1 and IDH2 mutations are also present in 23% of acute myeloid leukemia, but are rarely observed in other types of cancers, suggesting that IDH1 mutants are dependent on specific cell type or cell environment. By far, the most common mutation seen in glioma patients is IDH1 R132H. The inventors have generated and isolated xenografts and cell lines having a different IDH1 status (i.e., /DH7R132H heterozygous and 7DH7R132H homozygous) from dissociated glioblastoma multiforme (GBM) samples.
  • GBM dissociated glioblastoma multiforme
  • cell lines and xenografts are useful as tools for determining the impact of IDH1 R132H on cellular biology, tumorigenesis, viability, apoptosis, and metabolic profiles. These cell lines and xenografts can also be used for the discovery of new therapeutic targets and for the screening of novel molecular therapeutic agents.
  • the inventors have established and characterized stable, long-term human glioblastoma cell lines and xenografts that are homozygous or heterozygous for mutations in the IDH1 gene.
  • the established cell lines provide regents for studying tumor growth and the biological effects of IDH1.
  • the cell lines and xenografts are useful tools to test different therapeutic approaches, e.g., chemotherapeutic, radiological, nutritional, alternative, or biological, in a relevant disease model.
  • the cell lines can be used for studies in cell culture or can be transplanted into a laboratory animal, such as a nude mouse, to form a xenograft.
  • Xenografts can be tested in vivo in the animal, or they can be removed and tested in vitro.
  • cell lines having various IDH1 status e.g., wild-type, 7DH7R132H heterozygous, and 7DH7R132H homozygous
  • IDH1 status e.g., wild-type, 7DH7R132H heterozygous, and 7DH7R132H homozygous
  • these cell lines can be used as a tool for determining the impact of /DH7R132H on cellular biology, tumorigenesis, and metabolic profiles.
  • these cell lines can be used for the testing of therapeutic targets and for the screening of molecular therapeutic agents.
  • any means known in the art to generate a cell line which comprises a defective IDHI gene can be used to obtain the IDHI gene-defective cells.
  • an glioblastoma cell line can be used to give rise to an isogenic IDHI negative cell line by promoterless homologous recombination (see, e.g., Waldman, T. et al. (1995) Cancer Res. 55:5187-5190 , the contents of which are expressly incorporated by reference).
  • a primary glioblastoma cell can be used which already has an IDHI R132H mutation.
  • a cell with two wild-type alleles of the IDHI gene is a gene -normal cell, for purposes of the present disclosure.
  • a cell with one or two mutant IDHI alleles is termed an IDHI gene-defective cell.
  • the IDHI gene -normal cell used in the assay is the same type of cell (i.e., organ source) as the IDHI gene-defective cell. More preferably, the two cell lines are isogenic or as closely isogenic as possible.
  • Any of the IDHI alleles may be engineered to be present in a cell with any of the other alleles. Any of the alleles may be present in the heterozygous, homozygous, or hemizygous state. The presence of combinations of different alleles in a single cell may modify the phenotype.
  • Viability and cell death can be used as ways of assessing the effects of test agents on cells. Preferably a differential effect will be observed on an IDHI gene -normal cell and an IDHI gene-defective cell. Any assay for such effects can be used. In whole animals, regression of tumors can be observed. Alternatively, disease-free progression can be observed. Optionally, a change in survival can be observed. It is well known in the art that viability of a cell in culture can be determined by contacting the cell with a dye and viewing it under a microscope. Viable cells can be observed to have an intact membrane and do not stain, whereas dying or dead cells having "leaky" membranes do stain. Incorporation of the dye by the cell indicates the death of the cell.
  • Viability of cells can also be determined by detecting DNA synthesis.
  • Cells can be cultured in cell medium with labeled nucleotides, e.g., 3 H-Thymidine. The uptake or incorporation of the labeled nucleotides indicates DNA synthesis.
  • colonies formed by cells cultured in medium indicate cell growth and is another way to test viability of the cells.
  • Apoptosis is a specific mode of cell death recognized by a characteristic pattern of morphological, biochemical, and molecular changes. Cells going through apoptosis appear shrunken, and rounded; they also can be observed to become detached from culture dish. The morphological changes involve a characteristic pattern of condensation of chromatin and cytoplasm which can be readily identified by microscopy. When stained with a DNA-binding dye, e.g., H33258, apoptotic cells display classic condensed and punctate nuclei instead of homogeneous and round nuclei.
  • a DNA-binding dye e.g., H33258
  • a hallmark of apoptosis is endonucleolysis, a molecular change in which nuclear DNA is initially degraded at the linker sections of nucleosomes to give rise to fragments equivalent to single and multiple nucleosomes.
  • DNA fragments When these DNA fragments are subjected to gel electrophoresis, they reveal a series of DNA bands which are positioned approximately equally distant from each other on the gel. The size difference between the two bands next to each other is about the length of one nucleosome, i.e., 120 base pair.
  • This characteristic display of the DNA bands is called a DNA ladder and it indicates apoptosis of the cell.
  • Apoptotic cells can be identified by flow cytometric methods based on measurement of cellular DNA content, increased sensitivity of DNA to denaturation, or altered light scattering properties. These methods are well known in the art and are within the scope of the present disclosure.
  • DNA breaks are also characteristic of apoptosis and can be detected by any means known in the art.
  • DNA breaks are labeled with biotinylated dUTP (b-dUTP).
  • b-dUTP biotinylated dUTP
  • Cells are fixed and incubated in the presence of biotinylated dUTP with either exogenous terminal transferase (terminal DNA transferase assay; TdT assay) or DNA polymerase (nick translation assay; NT assay).
  • TdT assay exogenous terminal transferase assay
  • NT assay DNA polymerase
  • Morphology includes microscopic observations for features such as nuclear shape, and texture and contrast of nuclear and cytoplasmic staining. If desired, the Pathological and Analytic Imaging Standards can be used. This database provides query capabilities for the recall and analysis of the hundreds of millions of cells represented in each dataset. Any accepted morphological criteria for evaluating glioblastoma morphology can be used.
  • cell line refers to individual cells, harvested cells, and cultures containing the cells, so long as they are derived from cells of the cell line referred to.
  • a cell line is said to be “continuous,” “immortal,” or “stable” if the line remains viable over a prolonged time, typically at least about six (6) months. Preferably, the cells remain viable for at least 40 passages.
  • the term "gene-defective" refers to a cell(s) which lack one or two wild-type alleles or is deficient in that particular gene function. The defects may be due to abnormal expression of the gene or a mutation in the gene itself.
  • the gene-defective cell lacks both wild- type gene alleles, i.e., is homozygous.
  • the gene- defective cell lacks one wild-type gene alleles, i.e., is heterozygous.
  • the gene is isocitrate dehydrogenase (IDH).
  • the gene is isocitrate dehydrogenase 1 (IDH1).
  • a cell line is said to be “malignant” or “tumorigenic” if, when the cell line is injected into a host animal develops tumors or cancers that are anaplastic, invasive, and/or metastatic.
  • a "human” tumor is comprised of cells that have human chromosomes. Such tumors include those in a human patient, and tumors resulting from the introduction of a human malignant cell line into a non-human host animal for at least about one month.
  • cell line refers to individual cells, harvested cells, and cultures containing the cells, so long as they are derived from cells of the cell line referred to.
  • a cell line is said to be “continuous,” “immortal,” or “stable” if the line remains viable over a prolonged time, typically at least about six (6) months. Preferably, the cells remain viable for at least 40 passages.
  • Such cell lines are said to grow indefinitely in culture.
  • a cell line is said to be “malignant” or “tumorigenic” if, when the cell line is injected into a host animal, the animal develops tumors or cancers that are anaplastic, invasive, and/or metastatic.
  • a "human” tumor is comprised of cells that have human chromosomes. Such tumors include those in a human patient, and tumors resulting from the introduction of a human malignant cell line into a non-human host animal for at least about one week, one month, or several months.
  • Example 1 Generation of IDH1R132H homozygous human GBM xenogra fts and cell lines.
  • TB08-0174 (7DH/R132H homozygous) human GBM xenograft and cell lines were derived from a 31 year old female patient with a secondary human GBM.
  • Subcutaneous tumor xenografts were generated from the tumor tissues. It has become a well-established line with over 24 passages.
  • Genomic DNA from passage #9 xenograft has been sequenced for common glioma gene mutations.
  • the xenograft tumor contains homozygous 7DH7R132H mutation, PTEN c.333G>A, p.Wl 1 IX mutation, ERBB2 c.2444G>AG, p.G815E mutation.
  • Example 2 Generation of IDH1R132H heterozygous human GBM xenografts and cell lines.
  • TB08-0537 (7DH7R132H heterozygous) human GBM xenograft and cell lines were derived from a 37 year old female patient with secondary human GBM.
  • Subcutaneous tumor xenografts were generated from the tumor tissues. It has become a well-established line with over 23 passages.
  • Genomic DNA from passage #5 xenograft has been sequenced for common glioma gene mutations.
  • the xenograft tumor contains a heterozygous 7DH7R132H mutation, PTEN c.290A>T, p.Q97L mutation, and c.818G>A, p.R273H TP53 mutation.
  • PIK3R1 x7-14
  • ERBB2 ERBB2
  • RBI ERBB2
  • IDH1R132, PTEN and TP53 mutations were also found in the primary tumor biopsy.
  • the human tumor cells have been purified from the xenografts and grown in vitro.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)

Abstract

IDH1-mutant cell lines and xenografts (e.g., IDH1R132H heterozygous and IDH1R132H homozygous) are derived from human glioblastoma multiforme (GBM) samples. Methods use said cells and xenografts as tools for determining the impact of IDH1R132H on cancer properties including cellular morphology, tumorigenesis, DNA, apoptosis, and metabolic profiles. Methods also use these cell lines for the screening and identification of candidate therapeutic targets.

Description

IDH1- MUTATED HUMAN GLIOBLASTOMA CELL LINES AND
XENOGRAFTS
[01] This invention was made using funds from the U.S. National Institutes of Health, National Cancer Institute grant no. 1-R37-CA11898. The U.S. government retains certain rights in the invention under the terms of the grant.
[02] This application claims the benefit of provisional application U.S. 61/568,398 filed December 08, 2011, the contents of which are expressly incorporated herein.
BACKGROUND OF THE INVENTION
[03] Mutations in the isocitrate dehydrogenase genes IDH1 and IDH2 occur at an exceptionally high frequency (80%) in gliomas. The mutations also present in 23% of acute myeloid leukemia, and are rarely observed in other types of cancers. The frequency, specificity, and early timing of IDH mutations provide strong evidence for their importance in tumorigenesis, prognosis and therapeutics. However, the functional effects and significance of IDH mutations in human cancer have not been defined. Currently, a major limitation of the field is that there are no glioblastoma cell line or xenograft models which recapitulate IDH mutation-dependent tumor progression.
[04] There is a need in the art for glioblastoma (GBM) cell lines and xenograft models. SUMMARY OF THE INVENTION
[05] One aspect of the invention is an isolated human GBM xenograft identified as TB08-0714 (7DH7R132H homozygous) or as TB08-0537 (7DH7R132H heterozygous).
[06] Another aspect of the invention is an isolated human GBM cell line identified as TB08-0714 (7DH7R132H homozygous) or as TB08-0537 (7DH7R132H heterozygous).
[07] According to another aspect of the invention a method determines the effect of a test compound on DNA accumulation in an IDHl gene-defective cell line or xenograft of TB08-0714 (7DH7R132H homozygous) or TB08-0537 ( DH7R132H heterozygous). The IDHl gene-defective cell line or xenograft is incubated in the presence and absence of the test compound. The DNA content in the IDHl gene-defective cell or xenograft is determined. The test compound is selected if it causes DNA accumulation in the IDHl gene- defective cell or xenograft.
[08] According to another aspect of the invention a method screens for potential anti-tumor agents using an IDHl gene-defective cell line or xenograft. An IDHl gene-defective cell or xenograft (TB08-0714 (7DH7R132H homozygous) or TB08-0537 ( DH7R132H heterozygous)) is incubated in the presence and absence of the anti-tumor agents. Cell viability or apoptosis of the IDHl gene-defective cell or xenograft is determined. Anti-tumor agents which reduce cell viability or induce apoptosis in the IDHl gene-defective cell or xenograft are selected.
[09] According to another aspect of the invention a method screens for the effect of a test compound. A xenograft derived from IDHl gene-defective cells (TB08- 0714 (7DH7R132H homozygous) or TB08-0537 (7DH7R132H heterozygous) is incubated in the presence and absence of the test compound. Tumor morphology of the cells or xenograft is determined. A test compound that reduces the cancerous morphology or increases the normal morphology is selected.
[010] These and other embodiments provide the art with cell lines which can be used for screening potential anti-tumor agents.
BRIEF DESCRIPTION OF THE DRAWINGS
[011] FIG. 1 provides a Kaplan-Meir curve for IDH1 mutant xenoline NOD SCID IC. The 08-0537 or 08-0714 cells were injected intracranially for this survival study. The 50% survival time is 52 days and 58 days for 08-0537 and 08-0714 respectively.
[012] FIG. 2 shows IDH1 mutant tumor in NOD SCID mice (Xeno 08-0537, prefrontal injection) The xenograft images were taken from NOD SCID mice that have been intracranially injected with either 08-0537 cells. The mice were sacrificed and the brains were fixed for sections and pathological assessment when the mice showed symptoms.
[013] FIG. 3 shows IDH1 mutant tumor in NOD SCID mice ( Xeno 08-0714, prefrontal injection) The xenograft images were taken from NOD SCID mice that have been intracranially injected with either 08-0714 cells. The mice were sacrificed and the brains were fixed for sections and pathological assessment when the mice showed symptoms
DETAILED DESCRIPTION
[014] IDH1 gene mutations that affect amino acid 132 of IDH1 occur in an exceptionally high frequency (more than 70%) in gliomas. IDH1 and IDH2 mutations are also present in 23% of acute myeloid leukemia, but are rarely observed in other types of cancers, suggesting that IDH1 mutants are dependent on specific cell type or cell environment. By far, the most common mutation seen in glioma patients is IDH1 R132H. The inventors have generated and isolated xenografts and cell lines having a different IDH1 status (i.e., /DH7R132H heterozygous and 7DH7R132H homozygous) from dissociated glioblastoma multiforme (GBM) samples. These cell lines and xenografts are useful as tools for determining the impact of IDH1 R132H on cellular biology, tumorigenesis, viability, apoptosis, and metabolic profiles. These cell lines and xenografts can also be used for the discovery of new therapeutic targets and for the screening of novel molecular therapeutic agents.
[015] The inventors have established and characterized stable, long-term human glioblastoma cell lines and xenografts that are homozygous or heterozygous for mutations in the IDH1 gene. The established cell lines provide regents for studying tumor growth and the biological effects of IDH1. The cell lines and xenografts are useful tools to test different therapeutic approaches, e.g., chemotherapeutic, radiological, nutritional, alternative, or biological, in a relevant disease model. The cell lines can be used for studies in cell culture or can be transplanted into a laboratory animal, such as a nude mouse, to form a xenograft. Xenografts can be tested in vivo in the animal, or they can be removed and tested in vitro.
[016] In order to study directly the effect of IDH1 gene mutations in human cancer cells the inventor(s) have generated cell lines having various IDH1 status (e.g., wild-type, 7DH7R132H heterozygous, and 7DH7R132H homozygous) from dissociated primary human glioblastoma samples. These cell lines can be used as a tool for determining the impact of /DH7R132H on cellular biology, tumorigenesis, and metabolic profiles. Moreover, these cell lines can be used for the testing of therapeutic targets and for the screening of molecular therapeutic agents.
[017] Any means known in the art to generate a cell line which comprises a defective IDHI gene can be used to obtain the IDHI gene-defective cells. For example, an glioblastoma cell line can be used to give rise to an isogenic IDHI negative cell line by promoterless homologous recombination (see, e.g., Waldman, T. et al. (1995) Cancer Res. 55:5187-5190 , the contents of which are expressly incorporated by reference). Alternatively, as described below, a primary glioblastoma cell can be used which already has an IDHI R132H mutation. A cell with two wild-type alleles of the IDHI gene is a gene -normal cell, for purposes of the present disclosure. A cell with one or two mutant IDHI alleles is termed an IDHI gene-defective cell. Preferably, the IDHI gene -normal cell used in the assay is the same type of cell (i.e., organ source) as the IDHI gene-defective cell. More preferably, the two cell lines are isogenic or as closely isogenic as possible.
[018] Any of the IDHI alleles may be engineered to be present in a cell with any of the other alleles. Any of the alleles may be present in the heterozygous, homozygous, or hemizygous state. The presence of combinations of different alleles in a single cell may modify the phenotype.
[019] Viability and cell death can be used as ways of assessing the effects of test agents on cells. Preferably a differential effect will be observed on an IDHI gene -normal cell and an IDHI gene-defective cell. Any assay for such effects can be used. In whole animals, regression of tumors can be observed. Alternatively, disease-free progression can be observed. Optionally, a change in survival can be observed. It is well known in the art that viability of a cell in culture can be determined by contacting the cell with a dye and viewing it under a microscope. Viable cells can be observed to have an intact membrane and do not stain, whereas dying or dead cells having "leaky" membranes do stain. Incorporation of the dye by the cell indicates the death of the cell. The most common dye used in the art for this purpose is trypan blue. Viability of cells can also be determined by detecting DNA synthesis. Cells can be cultured in cell medium with labeled nucleotides, e.g., 3H-Thymidine. The uptake or incorporation of the labeled nucleotides indicates DNA synthesis. In addition, colonies formed by cells cultured in medium indicate cell growth and is another way to test viability of the cells.
[020] Apoptosis is a specific mode of cell death recognized by a characteristic pattern of morphological, biochemical, and molecular changes. Cells going through apoptosis appear shrunken, and rounded; they also can be observed to become detached from culture dish. The morphological changes involve a characteristic pattern of condensation of chromatin and cytoplasm which can be readily identified by microscopy. When stained with a DNA-binding dye, e.g., H33258, apoptotic cells display classic condensed and punctate nuclei instead of homogeneous and round nuclei.
[021] A hallmark of apoptosis is endonucleolysis, a molecular change in which nuclear DNA is initially degraded at the linker sections of nucleosomes to give rise to fragments equivalent to single and multiple nucleosomes. When these DNA fragments are subjected to gel electrophoresis, they reveal a series of DNA bands which are positioned approximately equally distant from each other on the gel. The size difference between the two bands next to each other is about the length of one nucleosome, i.e., 120 base pair. This characteristic display of the DNA bands is called a DNA ladder and it indicates apoptosis of the cell. Apoptotic cells can be identified by flow cytometric methods based on measurement of cellular DNA content, increased sensitivity of DNA to denaturation, or altered light scattering properties. These methods are well known in the art and are within the scope of the present disclosure.
[022] Abnormal DNA breaks are also characteristic of apoptosis and can be detected by any means known in the art. In one preferred embodiment, DNA breaks are labeled with biotinylated dUTP (b-dUTP). Cells are fixed and incubated in the presence of biotinylated dUTP with either exogenous terminal transferase (terminal DNA transferase assay; TdT assay) or DNA polymerase (nick translation assay; NT assay). The biotinylated dUTP is incorporated into the chromosome at the places where abnormal DNA breaks are repaired, and are detected with fluorescein conjugated to avidin under fluorescence microscopy.
[023] Morphology includes microscopic observations for features such as nuclear shape, and texture and contrast of nuclear and cytoplasmic staining. If desired, the Pathological and Analytic Imaging Standards can be used. This database provides query capabilities for the recall and analysis of the hundreds of millions of cells represented in each dataset. Any accepted morphological criteria for evaluating glioblastoma morphology can be used.
[024] The present disclosure is not limited in its application to the details of construction and the arrangement of components set forth in the following description. The invention described in the present disclosure is capable of other embodiments and of being practiced or of being carried out in various ways. Also, the phraseology and terminology used herein is for the purpose of description and should not be regarded as limiting.
[025] The use of "including," "comprising," "having," "containing," "involving," and variations thereof herein, is meant to encompass the items listed thereafter and equivalents thereof as well as additional items. For the purposes of promoting an understanding of the principles of the present disclosure, reference will now be made to preferred embodiments and specific language will be used to describe the same.
[026] The articles "a" and "an" are used herein to refer to one or to more than one (i.e. at least one) of the grammatical object of the article. By way of example, "an element" means at least one element and can include more than one element. Definitions
[027] While the following terms are believed to be well understood by one of ordinary skill in the art, the following definitions are set forth to facilitate explanation of the presently disclosed subject matter. Although any methods, devices, and materials similar or equivalent to those described herein can be used in the practice or testing of the presently disclosed subject matter, representative methods, devices and materials are now described.
[028] The term "cell line," as used herein, refers to individual cells, harvested cells, and cultures containing the cells, so long as they are derived from cells of the cell line referred to. A cell line is said to be "continuous," "immortal," or "stable" if the line remains viable over a prolonged time, typically at least about six (6) months. Preferably, the cells remain viable for at least 40 passages.
[029] As used herein, the term "gene-defective" refers to a cell(s) which lack one or two wild-type alleles or is deficient in that particular gene function. The defects may be due to abnormal expression of the gene or a mutation in the gene itself. In certain embodiments, the gene-defective cell lacks both wild- type gene alleles, i.e., is homozygous. In other embodiments, the gene- defective cell lacks one wild-type gene alleles, i.e., is heterozygous. In some embodiments, the gene is isocitrate dehydrogenase (IDH). In certain embodiments, the gene is isocitrate dehydrogenase 1 (IDH1).
[030] A cell line is said to be "malignant" or "tumorigenic" if, when the cell line is injected into a host animal develops tumors or cancers that are anaplastic, invasive, and/or metastatic. A "human" tumor is comprised of cells that have human chromosomes. Such tumors include those in a human patient, and tumors resulting from the introduction of a human malignant cell line into a non-human host animal for at least about one month.
[031] The present disclosure is not limited in its application to the details of construction and the arrangement of components set forth in the following description. The invention described in the present disclosure is capable of other embodiments and of being practiced or of being carried out in various ways. Also, the phraseology and terminology used herein is for the purpose of description and should not be regarded as limiting.
[032] The use of "including," "comprising," "having," "containing," "involving," and variations thereof herein, is meant to encompass the items listed thereafter and equivalents thereof as well as additional items. For the purposes of promoting an understanding of the principles of the present disclosure, reference will now be made to preferred embodiments and specific language will be used to describe the same.
[033] The articles "a" and "an" are used herein to refer to one or to more than one (i.e. at least one) of the grammatical object of the article. By way of example, "an element" means at least one element and can include more than one element.
[034] While the following terms are believed to be well understood by one of ordinary skill in the art, the following definitions are set forth to facilitate explanation of the presently disclosed subject matter. Although any methods, devices, and materials similar or equivalent to those described herein can be used in the practice or testing of the presently disclosed subject matter, representative methods, devices and materials are described.
[035] The term "cell line," as used herein, refers to individual cells, harvested cells, and cultures containing the cells, so long as they are derived from cells of the cell line referred to. A cell line is said to be "continuous," "immortal," or "stable" if the line remains viable over a prolonged time, typically at least about six (6) months. Preferably, the cells remain viable for at least 40 passages. Such cell lines are said to grow indefinitely in culture.
[036] A cell line is said to be "malignant" or "tumorigenic" if, when the cell line is injected into a host animal, the animal develops tumors or cancers that are anaplastic, invasive, and/or metastatic. A "human" tumor is comprised of cells that have human chromosomes. Such tumors include those in a human patient, and tumors resulting from the introduction of a human malignant cell line into a non-human host animal for at least about one week, one month, or several months.
[037] The following examples are provided for exemplification purposes only and are not intended to limit the scope of the disclosure which has been described in broad terms above.
EXAMPLES
Example 1: Generation of IDH1R132H homozygous human GBM xenogra fts and cell lines.
[038] TB08-0174 (7DH/R132H homozygous) human GBM xenograft and cell lines were derived from a 31 year old female patient with a secondary human GBM. Subcutaneous tumor xenografts were generated from the tumor tissues. It has become a well-established line with over 24 passages. Genomic DNA from passage #9 xenograft has been sequenced for common glioma gene mutations. The xenograft tumor contains homozygous 7DH7R132H mutation, PTEN c.333G>A, p.Wl 1 IX mutation, ERBB2 c.2444G>AG, p.G815E mutation. No mutation was identified in TP53, RBI or PIK3R1 (X7-14). IDH1R132 mutation was also found in the primary tumor biopsy. But PTEN or ERBB2 mutations were not revealed in the tumor biopsy. The human tumor cells have been purified from the xenografts and grown in vitro.
Example 2: Generation of IDH1R132H heterozygous human GBM xenografts and cell lines.
[039] TB08-0537 (7DH7R132H heterozygous) human GBM xenograft and cell lines were derived from a 37 year old female patient with secondary human GBM. Subcutaneous tumor xenografts were generated from the tumor tissues. It has become a well-established line with over 23 passages. Genomic DNA from passage #5 xenograft has been sequenced for common glioma gene mutations. The xenograft tumor contains a heterozygous 7DH7R132H mutation, PTEN c.290A>T, p.Q97L mutation, and c.818G>A, p.R273H TP53 mutation. No mutation was identified in PIK3R1 (x7-14), ERBB2 or RBI . The IDH1R132, PTEN and TP53 mutations were also found in the primary tumor biopsy. The human tumor cells have been purified from the xenografts and grown in vitro.
[040] Any patents or publications mentioned in this specification are indicative of the levels of those skilled in the art to which the invention pertains. These patents and publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference. One skilled in the art will readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The present examples along with the methods, procedures, treatments, molecules, and specific compounds described herein are presently representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention as defined by the scope of the claims.

Claims

WE CLAIM:
1. An isolated human GBM xenograft identified as TB08-0714 (IDH1R132H homozygous).
2. An isolated human GBM cell line identified as TB08-0714 (IDH1R132H homozygous).
3. An isolated human GBM xenograft identified as TB08-0537 (IDH1R132H heterozygous).
4. An isolated human GBM cell line identified as TB08-0537 (IDH1R132H heterozygous).
5. A method for determining the effect of a test compound on DNA
accumulation in an IDHl gene-defective cell line or xenograft according to any one of the preceding claims, said method comprising:
incubating said IDHl gene-defective cell line or xenograft in the presence and absence of the test compound;
determining and comparing DNA content in said IDHl gene-defective cell or xenograft when incubated in the presence and absence of the test compound; and
selecting the test compound which causes DNA accumulation in said IDHl gene-defective cell or xenograft.
6. The method of claim 5 wherein the method is performed on a pair of isogenic cell lines or xenografts.
7. A method of screening candidate agents for potential as anti-tumor agents in an IDHl gene-defective cell line or xenograft comprising: incubating an IDHl gene-defective cell or xenograft according to any of claims 1-4 in the presence and absence of a candidate agent;
determining and comparing cell viability or apoptosis in the IDHl gene- defective cell or xenograft in the presence and absence of the candidate agent; and
selecting the candidate agent as a potential anti-tumor agent which reduces cell viability or induces apoptosis in the IDHl gene-defective cell or xenograft.
8. The method of claim 7 wherein the method is performed on a pair of isogenic cell lines or xenografts.
9. A method for screening the effect of a test compound comprising:
incubating a xenograft according to claims 1 or 3 in the presence and in the absence of the test compound;
determining and comparing morphology of the xenograft in the presence and absence of the test compound; and
selecting the test compound which reduces the tumor morphology or increases the normal morphology.
10. The method of claim 9 wherein the method is performed on a pair of isogenic cell lines or xenografts.
11. The method of claim 9 wherein the step of incubating is performed in vivo in an experimental mammal.
12. The method of claim 5 wherein the IDHl gene-defective cell line is incubated.
13. The method of claim 7 wherein the IDHl gene-defective cell line is incubated.
14. The method of claim 5 wherein the IDHl gene-defective xenograft is
incubated.
The method of claim 7wherein the IDHl gene-defective xenograft
incubated.
PCT/US2012/068774 2011-12-08 2012-12-10 Idh1-mutated human glioblastoma cell lines and xenografts WO2013086506A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/364,029 US20140356291A1 (en) 2011-12-08 2012-12-10 IDH1-Mutated Human Glioblastoma Cell Lines and Xenografts

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161568398P 2011-12-08 2011-12-08
US61/568,398 2011-12-08

Publications (1)

Publication Number Publication Date
WO2013086506A1 true WO2013086506A1 (en) 2013-06-13

Family

ID=48574983

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/068774 WO2013086506A1 (en) 2011-12-08 2012-12-10 Idh1-mutated human glioblastoma cell lines and xenografts

Country Status (2)

Country Link
US (1) US20140356291A1 (en)
WO (1) WO2013086506A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106957367A (en) * 2017-03-31 2017-07-18 北京爱仁医疗科技有限公司 Anti- IDH1 R132H antibody and its production and use
WO2017213910A1 (en) 2016-06-06 2017-12-14 Eli Lilly And Company Mutant idh1 inhibitors

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113621574B (en) * 2021-08-13 2023-09-01 四川大学华西医院 Cell strain for resisting human glioblastoma radiotherapy and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010063300A1 (en) * 2008-12-03 2010-06-10 Università Degli Studi Di Torino Isogenic human cell lines comprising mutated cancer alleles and process using the cell lines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010063300A1 (en) * 2008-12-03 2010-06-10 Università Degli Studi Di Torino Isogenic human cell lines comprising mutated cancer alleles and process using the cell lines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ICHIMURA ET AL.: "IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas.", NEURO-ONCOLOGY, vol. 11, no. 4, 2009, pages 341 - 347 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017213910A1 (en) 2016-06-06 2017-12-14 Eli Lilly And Company Mutant idh1 inhibitors
CN106957367A (en) * 2017-03-31 2017-07-18 北京爱仁医疗科技有限公司 Anti- IDH1 R132H antibody and its production and use
CN106957367B (en) * 2017-03-31 2020-02-21 北京爱仁医疗科技有限公司 anti-IDH 1R132H antibody and preparation method and application thereof

Also Published As

Publication number Publication date
US20140356291A1 (en) 2014-12-04

Similar Documents

Publication Publication Date Title
AU2016201730B2 (en) Identification and enrichment of cell subpopulations
Daniel et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro
Bustamante et al. Uveal melanoma pathobiology: Metastasis to the liver
Xia et al. Identification of a cell-of-origin for fibroblasts comprising the fibrotic reticulum in idiopathic pulmonary fibrosis
Teicher Searching for molecular targets in sarcoma
McGowan et al. Reduced ribosomal protein gene dosage and p53 activation in low-risk myelodysplastic syndrome
Busch et al. Re-characterization of established human retinoblastoma cell lines
Koutelou et al. USP22 controls multiple signaling pathways that are essential for vasculature formation in the mouse placenta
Taylor et al. Modeling Diamond Blackfan anemia in the zebrafish
Triviai et al. ASXL1/EZH2 mutations promote clonal expansion of neoplastic HSC and impair erythropoiesis in PMF
Ishii et al. Absence of p53 gene mutations in a tumor panel representative of pilocytic astrocytoma diversity using a p53 functional assay
Baer et al. Fibrosis induced by resident macrophages has divergent roles in pancreas inflammatory injury and PDAC
US9695400B2 (en) Homozygous and heterozygous IDH1 gene-defective human astrocytoma cell lines
US20140356291A1 (en) IDH1-Mutated Human Glioblastoma Cell Lines and Xenografts
Hayes et al. Discovering novel oncogenic pathways and new therapies using zebrafish models of sarcoma
WO2017114007A1 (en) Pml gene and rara gene detection probe, preparation method therefor, and test kit
Luo et al. Stepwise crosstalk between aberrant Nf1, Tp53 and Rb signalling pathways induces gliomagenesis in zebrafish
CN102747096B (en) Gene search vector, random gene mutation control method and application thereof
CN102365372B (en) Prediction and monitoring are for the mark of replying of Aurora A B inhibitor therapy
US20080311092A1 (en) Murine Stem Cells and Applications Thereof
WO2017114008A1 (en) Bcr gene and abl gene detection probe, preparation method therefor, and reagent kit
WO2017114006A1 (en) Aml1 gene and eto gene detection probe, preparation method therefor, and test kit
US9074221B2 (en) Homozygous and heterozygous IDH1 gene-defective cell lines derived from human colorectal cells
CN105385781B (en) Application of the LCE3E in diagnosis and treatment carcinoma of mouth
Mott et al. Utility of EGFR and PTEN numerical aberrations in the evaluation of diffusely infiltrating astrocytomas

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12854938

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12854938

Country of ref document: EP

Kind code of ref document: A1